chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 07-JAN-2015 the patient was vaccinated with an improperly stored dose of M-M-R II 0.5ml, (HSA, lot # J006995, expiration date 14-JUN-2015). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion six times. The total cumulative excursion time of the first time was 344 hours with the highest recorded temperature of 6 Fahrenheit degree. The total cumulative excursion time of the second time was 160 hours with the highest recorded temperature of 10 Fahrenheit degree. The total cumulative excursion time of the third time was 48 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the fourth time was 64 hours with the highest recorded temperature of 17 Fahrenheit degree. The total cumulative excursion time of the fifth time was 40 hours with the highest recorded temperature of 47 Fahrenheit degree. The total cumulative excursion time of the sixth time was 72 hours with the lowest recorded temperature of 28 Fahrenheit degree. The storage criteria were refrigerator/freezer (R/F) and the type of excursion for this vaccine of the first, second and fourth time) was freezer (F); the type of excursion for this vaccine of the other times was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
3? round deep red mark at injection site with extreme bicep pain radiating around arm. Hot to touch and weakness in arm.
Patient received the Covid Pfizer 5-11 Bivalent vaccine for her first dose of her primary series, instead of the Monovalent COVID vaccine as part of the primary series.
She reports a female of adolescent age fainted after receiving GARDASIL 9.; This spontaneous report was received from a physician via field representative, referring to a female adolescent patient of unknown age. The patient's pertinent medical history, previous drug allergies or reactions, and concomitant medications were unknown by the reporter.  On an unknown date in 2020 (also reported as "sometime in 2020"), the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (formulation, dose, route of administration, vaccination scheme frequency, anatomical site of vaccination, lot number, and expiration date were unknown) as prophylaxis.   On an unknown date in 2020 (also reported as "sometime in 2020"), after receiving the vaccine, the patient fainted (syncope). It was unknown if the patient received treatment for the adverse event, if laboratory diagnostics or studies were performed, or if the patient sought medical attention.  The outcome of the event syncope, and the causal relationship between the event syncope and hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) were not provided.   Upon internal review, the event syncope was considered to be medically significant.  This is one of two reports received from the same reporter.; Sender's Comments:  US-009507513-2102USA008675:
I broke out with 6 blisters on my face about a week - 10 days after I received the shot. They lasted a little more than 2 weeks. There was no pain. I have minor scars.
p/vax erythema & edematous area @ inj site approx 2x2";pt reported no pain;afeb;
Minutes after receiving the shot, the patient began to feel light headed.  Shortly after, she slumped over in the chair where we ask patients to sit after the shots are administered.  The staff pharmacist attended to the patient immediately and stayed with her throughout the incident.  She was unresponsive at first, but eventually would rotate between moments of consciousness and syncope.  She had to vomit once, had hot flashes, and was disoriented. We focused on trying to keep her attention and preventing her from losing consciousness again.  We provided an ice pack to help with her hot flashes.  An ambulance was notified shortly into the event when it was apparent that she was not improving.  When the paramedics arrived, we provided as much information as we could. We were able to get in touch with a family member, and the paramedics left with her on a stretcher.
Dizziness, Headache, Arthralgia, Fever, CoughWheeze, ErythemaMultiform, Diarrhea, NauseaVomiting, , fatigue - sudden sleep - 8 hrs, arm soreness, chills Narrative:
Rash on face and trunk. No blisters. No exanthema >72 degrees.
p/vax pt noticed itching @ inj site during 8Am shower;saw raised rash;Lt deltoid site had a bruise where pneumo vax given then a welt looking area;rash extending horizontally approx 2 1/2" to irregular depths of 1-1 1/2";warm to touch;
no treatment. High fever and flat out in bed or 3+ days. excessive sweating, bad headache, no appetite, no energy
Started with numbness in toes that progressed to numbness in feet, legs, and hands. The numbness then progressed to excruciating pain to extremities, chest, and face. I became extremely weak and could not walk without assistance. I was admitted to the hospital and diagnosed with Guillain Barre Syndrome and received IVIG treatment.
pt recv vax 20JUL98 & w/in hr has fever & ulcerations in mouth;dx herpangina;
Vaccine was the J & J one shot A few days after getting the shot I started to have pain in my shoulders and hip joints.   Feels like arthritis but very painful and seems to get worse every day.    Never had arthritis before in these areas so very concerned. It has been over 3 weeks now and pain medicine barely helps.
Injection site bruising, rash, with creeping red rash that continued to broaden each day.  Swelling, itchiness.  Minor wheezing (Day 2 or 3) Extreme fatigue (Day 1, 2, 3).
4 months after vaccination, patient developed a rash over one arm and on his upper back.  The doctor diagnosed him as having herpes voster, a result of his chicken pox vaccination.  He was given acyclovir for 5 days, 4 times a day.  He was in pain and itching for about a week.  Most of the rash has cleared up, but some remains as brownish/purplish spots, like bruising.
noted that the moderna booster was not the bivalent booster but the original moderna.  called the pt and informed her and she voiced no problems. provider was informed and office manager
1st dose Aug2021, 2nd not yet; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (patient received 1st dose in August 2021).   On an unknown date, the patient did not received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 21-OCT-2022 Reporter's Comment: The reporter stated that a patient had not yet received his second dose.   The patient would like to come in for the second dose today (on the date of reporting).   At the time of reporting, the second dose has not been administered.  The pharmacist just spoke to the patient over the phone and did not know his age, date of birth, exact date of first dose, or any lot number information from first dose. The reporter gave consent to follow up. Additional supportive information: VAERS details reported were corresponding to the 1st dose as the 2nd dose had not been received yet.
swollen left upper arms-no pain , ? reaction - cellulitis, keflex 250 mg, 3/4 tsp tod,cold compressions
ADVERSE EVENT; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch/lot number. No concomitant medications were reported. On an unspecified date, the patient experienced adverse event. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of adverse event was not reported. This report was non-serious.
Subjective symptoms: arm pain, fatigue, diaphoresis, shaky, headache. Serious adverse event: neutropenia and thrombocytopenia. Patient required filgastrim 480mcg subcutaneous once.
Headache,  fatigue, muscle ache, tachycardia,  sore throat (mild), severe pain at injection site limiting movement, eye pain and blurring. All began approximately 12 hours after vaccination. Did report to the ER at Summit Medical Center 2/3/2021 . Labs were drawn, ekg and cxr done. Md stated all normal. (I had pneumonia and was in a fib upon arrival to Vanderbilt Medical Center when I was admitted there with Covid in March 2020.)
started having severe lower back pain, then my lower lip went numb, two days later lost all control of my legs and could not walk anymore ..was found to have Guillain Barre Syndrome
This spontaneous report as received from a registered nurse refers to a 19-year-old patient of unknown gender. The patient's medical history, concurrent conditions and medical history were not provided. The reporting nurse stated that it might be possible that the patient received two doses of (Wistar RA 27-3) M-M-R I (dose, the dose number, albumin status, route of administration, lot number/expiration date were not provided) and two doses of Oka/Merck VARIVAX (dose, the dose number, route of administration, lot number/expiration date were not provided) on the same unspecified date. No adverse effects were reported.
I personally know 9 people who died from your vaccination; This is a spontaneous report from a non-contactable consumer reporting same event under the same suspect product for 9 patients. This is one of 9 reports. A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on unspecified date as single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Reporter stated, "I personally know 9 people who died from your vaccination. You reported 16,000 people have died, even the people who work for the company speaking on this." It was unknown if autopsy was done. The outcome of the event was fatal.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.No further information is expected.; Sender's Comments: Linked Report(s) : PFIZER INC-202101145863 Same reporter/drug/event, different patient.; Reported Cause(s) of Death: died from your vaccination
1st dose 2019, 2nd July2022; This case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 0.5 ml of first dose in unknown arm intramuscularly in 2019).   In July 2022, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. In July 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK receipt date: 9-Dec-2022 Reporter's comment: The caller did not gave permission to contact her health care professional. The caller did not consent to follow-up. Additional supportive information: The patient received second dose of Shingrix in unknown arm later than recommended interval, which led to lengthening of vaccine schedule.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 03/202/21Lot#ER8727 2nd dose 04/10/21 ,lot#EW0150 Diagnosed covid positive:08/13/21 Symptom onset: Exposure:Travel Symptoms:Asymptomatic
onset of dizzy spells, light-headiness, weakness, tired one hour after injection. Has persisted for 27 hours.
Pt complaint: numbness of left side of face. Exam indicated "vitals signs stable, cranial nerves intact, some drooping of the left side of face, slight drooling, eye opens and closes normally".
Made home visit for the 2nd dose of the Moderna COVID Vaccine and the daughter reported patient had died on 5/9/2021. No other information was given.
Dizziness, Headache,  chills and sweats Narrative:  Too ill to work
I was woken up from sleep at 2 AM with intense and audible stomach cramping and immediately vomited in the bathroom. For the next 48 hours I had continuous vomiting and diarrhea. I could not hold down food or water.  Finally the vomiting stopped after 48 hours but I continued to have diarrhea. I ended up taking Imodium because I was concerned about dehydration. After one dose of Imodium the diarrhea stopped.
Left upper with 4cm diameter blister, some mild erythema Treatment:  blister unroofed with sterile scissors and pick ups.  Some clear liquid was drained
Numbness in lower lip and numbness and slight trembling in right side of face (similar to Bells Palsy?) after four days of being administered the first shot in the right arm. After a video consult with my PCP it was recommended that I go to the hospital and get a CT scan to rule out a possible minor stroke. The CT scan was negative. The numbness became better after two weeks but has not subsided.  After consultation with the doctor in charge of the vaccine operation for the site it was decided that I go ahead and take the second shot but instead of the right arm I should take it in either the left arm or the left thigh. The second shot was administered in the left thigh. I experienced the typical symptoms on the second day - fever, chills and aches and pain but they went away towards the end of the second day. However, exactly on the fourth day I experienced increased numbness in my lower lip and on the right side of my face. Today is the fifth day and it is still there. I expect that this numbness will continue for several weeks as it did with the first shot and so far it has not subsided after the first shot and has now increased after the second shot. I am totally convinced that this is a direct result of the vaccine.
Onset generalized urticaria 1 wk post receiving flu and pneumonia vaccines not responding to Zyrtec. No respiratory, swallowing, breathing problems-no fever, chills, NVD. Required Medrol dose pack.
it was given in a place where there was no muscle so it probably went subcutaneous; nausea; headache; allergic reaction; one large hive on the injection arm but not at the site it was beside it; it grew in size and was very itchy and painful; it grew in size and was very itchy and painful; redness in the area it was given; This is a spontaneous report from a contactable consumer (patient). A 52-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number EN6205 and expiry date not reported), dose 1 via an unspecified route of administration on 01Mar2021 (at the age of 52-year-old), as dose 1, single, for COVID-19 immunisation. Medical history included asthma and several allergies to things she doesn't know of but has never had an anaphylactic reaction or used an epi pen for them. Her reactions have been hives and swelling in her mouth. There were no concomitant medications. The patient received the first dose of the Pfizer COVID vaccine on 01Mar2021 (reported as Monday). On the first day there was no issues. On 02Mar2021 (reported as Tuesday), the patient experienced an allergic reaction, one large hive on the injection arm but not at the site it was beside it and it grew in size and was very itchy and painful, she had terrible headache, nausea. The patient went to her primary doctor and they told her they didn't feel as though she had a severe reaction and she should be okay to receive the second dose of the vaccine. The primary doctor told her to ask her allergist for their opinion regarding her receiving the second dose. The patient saw the nurse practitioner there and they thought her reaction was severe and that she should not receive the second dose and told her to call Pfizer to see recommendations. The patient took Zofran for her nausea and Tylenol every 6 hours for headache. Her hives never went all over her body they stayed on her upper arm near injection site. The patient got her first dose on 01Mar2021 and finished her second dose on 22Mar2021 (lot number: EN6205). Two days before her second dose a nurse and her physician told that her first dose of vaccine was given improperly, administered subcutaneously and should have been intramuscularly and that was against protocol. They do not know if she would get the full protection, instead of being like 90 something percent covered she was really going to be like 50-55% covered with one dose, the second dose so she wants to find out if that was true. She also added that her second dose was given correctly. The patient asked if there was a way if she can know if she was protected and if Pfizer can recommend an antibody test. The patient also asked if there were any other vaccines given subcutaneously. The outcome for the events was unknown.  No follow-up attempts are possible. No further information is expected.
This is an initial spontaneous report from a contactable consumer from a Pfizer-sponsored program. A female patient of an unspecified age received first dose of BNT162B2(PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 02Feb2021 as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced 02feb2021 was first dose of the covid vaccine.11feb2021 had a positive covid test. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on 11Feb2021. The outcome of the events was unknown. Information about lot/batch number has been requested.
This case was reported by a nurse via call center representative and described the occurrence of injection site erythema in a 45-year-old female patient who received FLUARIX QUADRIVALENT (batch number C559A, expiry date 30th June 2018). On 3rd October 2017, the patient received FLUARIX QUADRIVALENT .5 ml. On 4th October 2017, 1 days after receiving FLUARIX QUADRIVALENT, the patient experienced injection site erythema, injection site warmth and injection site swelling. On 5th October 2017, the outcome of the injection site erythema, injection site warmth and injection site swelling were recovered/resolved. The reporter considered the injection site erythema, injection site warmth and injection site swelling to be related to FLUARIX QUADRIVALENT. Additional details were reported as follows: This case was previously reported to Doctor. The nurse that reported that, the day after the injection, the patient stated there was redness and swelling at the injection site. The patient mentioned that, the skin around the site was felt hot when touched. Two days later when spoke with the nurse, the patient's side effects were resolved.
Pt was given MENACTRA before he was at the recommended age to receive MENACTRA.  Pt age 10, 2 1/2 months early per CDC recommendations & guidelines.  Misadministration.
On the morning of 3/21/2023, I noticed that I had a sore throat. The sore throat lasted for a couple of days, and on 3/22/2023, I started to also feel tired. In the early hours of 3/23/2023, I woke up with an extremely sore throat. At 2:30 AM, I took a lateral flow COVID-19 test and got a positive result. On 3/23/2023, I had a telehealth visit with my doctor, who prescribed me Paxlovid. She also told me that I could take OTC medicines like Advil and Tylenol to manage discomfort. I began taking the Paxlovid on 3/24/2023. I soon started to feel better afterwards, though I continued to test positive. On 3/28/2023, I finished the Paxlovid. On 3/29/2023, I tested negative for COVID-19. After all of that, I continued to have issues with breathing and coughing for about three weeks afterwards. I ended up using my inhaler about two or three times during this period.
This spontaneous report was received from a physician via a company representative, referring to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 06-APR-2015, the patient was vaccinated with an improperly stored dose of GARDASIL which had a lot number of K007828 and expiration date on 02-MAR-2017 (route of administration and anatomical location were not reported). There were no concomitant medications provided. No adverse effects reported. No product quality complaint was involved. On an unspecified date, the GARDASIL vaccine had two temperature excursions; one for 488 hours with the lowest recorded temperature of 33 F (0.555555556 Celsius) and other one for 32 hours with lowest recorded temperature of 32 F (0 Celsius). The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator (R)". This is one of several cases from the same reporter. Additional information has been requested.
3 weeks after 2nd vaccine dose, patient noted new onset of 5-6 cystic acne pustules on her forehead. 3 months later cystic acne had spread to her entire face including cheeks and chin line, consisting of 35-40 painful, red pustules.  Sought medical treatment with doctor at that time and is being actively treated for symptoms since then.
onset of nausea 9pm and vomited once. no further symptoms except intermittent nausea 11/14 and 11/15. eating normally and no more vomiting.
Patient received vaccine and then was asked to wait around for 15 minutes. She came to the counter and when my technician went to help her she collapsed. We helped her into a chair and gave her some food and water. She told us she was coming to the counter to let us know she was dizzy and light headed. Asked her if she wanted us to call 911 or a friend or family member and she declined. She told me she is on a 500 calorie diet and that she ate prior to coming here
Passed out 9 hours after injection on 03Mar2021; This is a spontaneous report from a contactable consumer. A 43-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 via an unspecified route of administration on 03Mar2021 18:00 (Batch/Lot number was not reported) as SINGLE DOSE, and dose 1 via an unspecified route of administration, administered in Arm Right on 10Feb2021 18:00 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient previously took amoxicillin and experienced drug hypersensitivity. The patient experienced passed out 9 hours after injection/also reported as 03Mar2021 03:30. The outcome of the event was recovering. The patient did not receive treatment for the event.  Information on the Lot/Batch number has been requested.
Information has been received from a pharmacist referring to a 73 year old patient of unknown gender. On 02-JUL-2013, the patient was vaccinated with the first dose of ZOSTAVAX (lot#, expiration date, dose and route unknown). On 14-MAY-2015 the patient was vaccinated with the second dose of ZOSTAVAX lot # K018173 and expiration date 10-JAN-2016,0.65 ml, subcutaneously. Concomitant therapy included diphtheria toxoid, pertussis acellular vaccine (unspecified), tetanus toxoid. There was no adverse event reported. Additional information has been requested.
Fever of 101 degrees and chills along with body aches. Treatment: rest, tea, not taking care of my 5 day old son.
Headache, joint pain, arthritis, fibromyalgia, skin rashes and lesions, chronic fatigue, insomnia, severe pain, diminished vision, feeling like body being crushed, diarrhea, vomiting, extremes in weight gain and loss, unexplained rash, chest pain, shortness of breath, walk with a cane, mouth sores, memory loss, muscle cramps, just to list some of them.